Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,701–1,800 of 15,747
Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Aghayari Sheikh Neshin, S., Khatami, A., Turner, D. L., Djalalinia, S., Mousavi, S. A., Mardani-Fard, H. A., et al. (2021) · Vaccines · doi:10.3390/vaccines10010023 · Cited by 62
van de Ven, K., Lanfermeijer, J., van Dijken, H., Muramatsu, H., de Melo, C. V. B., Lenz, S., Peters, F., Beattie, M. B., Lin, P. J. C., Ferreira, J. A., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9937 · Cited by 70
McSweeney, M. D., Mohan, M., Commins, S. P., & Lai, S. K. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.715844 · Cited by 65
Varghese, E., Samuel, S. M., Líšková, A., Kubatka, P., & Büsselberg, D. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009634 · Cited by 68
Boucher, J.-C., Cornelson, K., Benham, J. L., Fullerton, M. M., Tang, T., Constantinescu, C., Mourali, M., Oxoby, R. J., Marshall, D. A., Hemmati, H., et al. (2021) · JMIR Infodemiology · doi:10.2196/28800 · Cited by 72
Vascular senescence and aging: mechanisms, clinical implications, and therapeutic prospects
Picos, A., Seoane, N., Campos‐Toimil, M., & Viña, D. (2025) · Biogerontology · doi:10.1007/s10522-025-10256-5 · Cited by 91
“For instance, lipid nano-particles have been successfully used in mRNA-based COVID-19 vaccines, demonstrating their potential for safe and effective delivery of nucleic acids (Baden et al. 2021; Polack et al. 2020).”
Popa, A. D., Enache, A. I., Popa, I. V., Antoniu, S. A., Dragomir, R. A., & Burlacu, A. (2022) · Vaccines · doi:10.3390/vaccines10050672 · Cited by 70
“Both Moderna (mRNA1273; Cambridge, MA, USA) and Pfizer BioNTech (BNT162b2; Mainz, Germany) COVID-19 vaccines offer protection greater than 90% [4,5], while Johnson & Johnson (Ad26.”
BackgroundIoannou, G. N., Locke, E. R., O’Hare, A. M., Bohnert, A. S. B., Boyko, E. J., Hynes, D. M., & Berry, K. (2021) · Annals of Internal Medicine · doi:10.7326/m21-3256 · Cited by 82
Costanzo, M., Giglio, M. A. R. D., & Roviello, G. N. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210521164809 · Cited by 71
Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination
Permezel, F., Borojevic, B., Lau, S., & de Boer, H. H. (2022) · Forensic Science, Medicine and Pathology · doi:10.1007/s12024-021-00440-7 · Cited by 62
Santos, C. S., Antolín, S. C., Morales, C. M., Herrero, J. G., Álvarez, E. D., Ortega, F. R., & de Morales, J. M. G. R. (2022) · RMD Open · doi:10.1136/rmdopen-2021-001898 · Cited by 66
Muhsen, K., Na'aminh, W., Lapidot, Y., Goren, S., Amir, Y., Perlman, S., Green, M. S., Chodick, G., & Cohen, D. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100130 · Cited by 62
“On December 19, 2020, Israel introduced the BNT162b2 mRNA vaccine [22] in a vigorous immunisation campaign.”
Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use
Vasireddy, D., Atluri, P., Malayala, S. V., Vanaparthy, R., & Mohan, G. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4490 · Cited by 66
Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines
Li, J., Wu, Y., Xiang, J., Wang, H., Zhuang, Q., Wei, T., Cao, Z., Gu, Q., Liu, Z., & Peng, R. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.140930 · Cited by 66
Li, D., Edwards, R. J., Manne, K., Martinez, D. R., Schäfer, A., Alam, S. M., Wiehe, K., Lu, X., Parks, R., Sutherland, L. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.31.424729 · Cited by 62
A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development
Abdulla, Z. A., Al-Bashir, S. M., Al-Salih, N. S., Aldamen, A. A., & Abdulazeez, M. Z. (2021) · Pathogens · doi:10.3390/pathogens10070788 · Cited by 66
“5% of people vaccinated with the Pfizer–BioNTech and Moderna vaccines, respectively [80,85,163].”
BackgroundQuantifying the COVID19 infection risk due to droplet/aerosol inhalation
Bale, R., Akiyoshi, I. I. D. A., Yamakawa, M., Li, C., & Tsubokura, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-14862-y · Cited by 66
Harrington, P., Doores, K. J., Radia, D. H., O’Reilly, A., Lam, H. P. J., Seow, J., Graham, C., Lechmere, T., McLornan, D. P., Dillon, R. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17568 · Cited by 65
“Large international randomised placebo-controlled studies have shown the efficacy of the BNT162b2 vaccine, with a two-dose regime resulting in a 95% reduction in cases in the general population.5 Evidence of a protective immune response to a single dose is shown by a reduction in cases of 52% reported in the interim b…”
BackgroundInfluentialCould a good night's sleep improve COVID-19 vaccine efficacy?
Benedict, C., & Cedernaes, J. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00126-0 · Cited by 71
Jiménez, M., Roldán, E., Fernández‐Naval, C., Villacampa, G. J., Martínez‐Gallo, M., Medina-Gil, D., Peralta, S., Pujadas, G., Hernández, C., Pagès, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006101 · Cited by 67
Saied, E. M., El‐Maradny, Y. A., Osman, A. A., Darwish, A. M. G., Nahas, H. H. A., Niedbała, G., Piekutowska, M., Abdel-Rahman, M. A., Balbool, B. A., & Abdel-Azeem, A. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111759 · Cited by 65
Paris, C., Perrin, S., Hamonic, S., Bourget, B., Roué, C., Brassard, O., Tadié, E., Gicquel, V., Bénézit, F., Thibault, V., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.06.043 · Cited by 62
Nejad, M.-M. M., Moosaie, F., Dehghanbanadaki, H., Ghadery, A. H., Shabani, M., Tabary, M., Aryannejad, A., SeyedAlinaghi, S., & Rezaei, N. (2022) · European journal of medical research · doi:10.1186/s40001-022-00648-5 · Cited by 69
“However, the application of COVID-19 vaccines in patients with impaired immune systems remains an ongoing subject of debate as they were excluded from the original trials [13, 14].”
America’s deadly flirtation with antiscience and the medical freedom movement
Hotez, P. J. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149072 · Cited by 65
Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine
Yamamoto, S., Mizoue, T., Tanaka, A., Oshiro, Y., Inamura, N., Konishi, M., Ozeki, M., Miyo, K., Sugiura, W., Sugiyama, H., et al. (2022) · Obesity · doi:10.1002/oby.23417 · Cited by 60
Pan, H., Liu, J., Huang, B., Li, G., Chang, X., Liu, Y., Wang, W., Chu, K., Hu, J., Li, J., et al. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001573 · Cited by 60
Complement dysregulation is associated with severe COVID-19 illness
Yu, J. M., Gerber, G. F., Chen, H., Yuan, X., Chaturvedi, S., Braunstein, E. M., & Brodsky, R. A. (2021) · Haematologica · doi:10.3324/haematol.2021.279155 · Cited by 64
“Length of hospitalization (days), median 9 (2-45) 11 (7-15) 28 (3-70) 17”
Aleksova, A., Gagno, G., Sinagra, G., Beltrami, A. P., Janjusevic, M., Ippolito, G., Zumla, A. I., Fluca, A. L., & Ferro, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094526 · Cited by 72
“Furthermore, trials evaluating BNT162b2, mRNA‐1273 and AZD1222 on elder individuals suggest that they are as safe as younger groups with the same antibody and cell response [91,109,110].”
BackgroundSibbel, S. P., Mckeon, K. L., Luo, J., Wendt, K., Walker, A. G., Kelley, T., Lazar, R., Zywno, M. L., Connaire, J. J., Tentori, F., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021060778 · Cited by 63
mRNA therapies: Pioneering a new era in rare genetic disease treatment
Shen, G., Liu, J., Yang, H., Xie, N., & Yang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.056 · Cited by 63
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies
Faour, W. H., Choaib, A., Issa, E., Choueiry, F. E., Shbaklo, K., Alhajj, M., Sawaya, R. T., Harhous, Z., Alefishat, E. A., & Nader, M. (2021) · Inflammation Research · doi:10.1007/s00011-021-01520-8 · Cited by 69
Perinatal SARS-CoV-2 Infection and Neonatal COVID-19: A 2021 Update
Sankaran, D., Nakra, N. A., Cheema, R., Blumberg, D. A., & Lakshminrusimha, S. (2021) · NeoReviews · doi:10.1542/neo.22-5-e284 · Cited by 85
Branche, A. R., Rouphael, N., Diemert, D. J., Falsey, A. R., Losada, C., Baden, L. R., Frey, S. E., Whitaker, J. A., Little, S. J., Anderson, E. J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02503-4 · Cited by 63
A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
Niu, L., Wittrock, K. N., Clabaugh, G. C., Srivastava, V., & Cho, M. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647934 · Cited by 65
“distinct non-neutralizing faces on the RBD, and (3) maximum of potentially four nAbs could”
BackgroundCOVID-19 vaccine induced rhabdomyolysis: Case report with literature review
Nassar, M., Chung, H., Dhayaparan, Y., Nyein, A., Acevedo, B. J., Chicos, C., Zheng, D. D., Barras, M., Mohamed, M., Alfishawy, M., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.06.007 · Cited by 61
“Vaccine Pfizer BioNTech (BNT162B2) [9] Moderna (MRNA-1273) [10] J&J (JNJ78436735) [11]”
Gounant, V., Ferré, V. M., Soussi, G., Charpentier, C., Flament, H., Houhou‐Fidouh, N., Collin, G., Namour, C., Assoun, S., Bizot, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.015 · Cited by 64
Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?
Brüssow, H., & Zuber, S. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13997 · Cited by 72
“Similar data were published for the mRNA vaccine of Pfizer-BioNTech, which showed a VE of 91% against symptomatic COVID-19 (Polack et al., 2020).”
ResultKlimek, L., Novak, N., Hamelmann, E. H., et al. (2021) · Allergo Journal International · doi:10.1007/s40629-020-00160-4 · Cited by 61
Kohmer, N., Rühl, C., Ciesek, S., & Rabenau, H. F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102128 · Cited by 62
“Local reactogenicity was also higher in the safety and efficacy trail of BNT162b2 in individuals younger than 55 years of age [35].”
BackgroundN1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products
Kim, K. Q., Burgute, B. D., Tzeng, S., Jing, C., Jungers, C. F., Zhang, J., Yan, L. L., Vierstra, R. D., Djuranović, S., Evans, B. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111300 · Cited by 73
Mao, Y., Wang, W., Ma, J., Wu, S., & Sun, F. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001892 · Cited by 66
Almendro-Vázquez, P., Laguna‐Goya, R., Ruiz‐Ruigómez, M., Utrero‐Rico, A., Lalueza, A., de la Calle, G. M., Delgado, P., Ordoño, L. P., Muro, E., Vila, J. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010211 · Cited by 63
“As described by the vaccine trials [21,22], a single dose of vaccine was insufficient to develop neutralizing antibodies (Fig 7H).”
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
Ashraf, M. U., Kim, Y., Kumar, S., Seo, D., Ashraf, M., & Bae, Y. (2021) · Vaccines · doi:10.3390/vaccines9020171 · Cited by 65
Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles
Krishnapriya, S., Jakubek, Z. J., Chen, S., Zaifman, J., Tam, Y. Y. C., & Zou, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-23013-2 · Cited by 70
Rottenstreich, A., Zarbiv, G., Oiknine‐Djian, E., Vorontsov, O. M., Zigron, R., Kleinstern, G., Wolf, D. G., & Porat, S. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.003 · Cited by 63
“Pregnantwomenwere excluded from the initial trials evaluating the different SARS-CoV-2 vaccines [19,20].”
Kerr, S., Bedston, S., Cezard, G. I., Sampri, A., Murphy, S., Bradley, D., Morrison, K., Akbari, A., Whiteley, W. N., Sullivan, C. B., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02467-4 · Cited by 71
Li, Y., & Champion, J. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114462 · Cited by 68
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 65
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans
Huang, K.-Y. A., Tan, T. K., Chen, T.-H., Huang, C.-G., Harvey, R., Hussain, S., Chen, C.-P., Harding, A., Gilbert-Jaramillo, J., Liu, X., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009352 · Cited by 73
Halfmann, P., Frey, S. J., Loeffler, K., Kuroda, M., Maemura, T., Armbrust, T., Yang, J. E., Hou, Y. J., Baric, R. S., Wright, E., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104341 · Cited by 55
Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington, E., Cole, M. J., Saei, A., Oguti, B., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3768524 · Cited by 59
Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients
Tsuzuki, S., Miyazato, Y., Terada, M., Morioka, S., Ohmagari, N., & Beutels, P. (2022) · Health and Quality of Life Outcomes · doi:10.1186/s12955-022-02033-6 · Cited by 67
Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa
Reddy, K. P., Fitzmaurice, K. P., Scott, J. A., Harling, G., Lessells, R. J., Panella, C., Shebl, F. M., Freedberg, K. A., & Siedner, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-26557-5 · Cited by 66
Ghosh, S., Shankar, S., Chatterjee, K., Chatterjee, K., Yadav, A. K., Pandya, K., Suryam, V., Agrawal, S., Ray, S., Phutane, V., et al. (2021) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2021.06.032 · Cited by 63
“Initial vaccine efficacy data was provided by the manufacturers.(5,6) Some early studies of vaccine effectiveness among population have been carried out in a few countries.”
BackgroundMaharjan, R., Hada, S., Lee, J., Han, H.-K., Kim, K. H., Seo, H. J., Foged, C., & Jeong, S. H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123012 · Cited by 69
Wong, K. K., Lee, S. W. H., & Kua, K. P. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s306849 · Cited by 65
Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review
Li, T., Huang, T., Guo, C., Wang, A., Shi, X., Mo, X., Lu, Q., Sun, J., Hui, T., Tian, G., et al. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100116 · Cited by 66
“For example, the Pfizer BNT162b2 vaccine exhibited 95% efficacy against the original SARS-CoV-2 strain.(101) However, recent in vitro studies investigating the efficacy of serum of BNT162b2-vaccinated volunteers showed roughly equivalent neutralization of recombinant viruses expressing the P.”
Clinical applications of gene therapy for rare diseases: A review
Papaioannou, I., Owen, J. S., & Yáñez‐Muñoz, R. J. (2023) · International Journal of Experimental Pathology · doi:10.1111/iep.12478 · Cited by 79
Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro
Huang, H., Lai, Y., Liao, C., Wang, F.-Y., Huang, K.-B., Lee, I., Chou, W., Wang, S., Wang, L., Hsu, J.-M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103712 · Cited by 65
“Several vaccines, such as mRNA-1273 and BNT162b2, have been developed to induce antibodies that neutralize S protein of the original WuhanHU-1 strain of SARS-CoV-2 (denoted WT hereafter) [4,5].”
(2021) · doi:10.1101/2021.12.12.472286 · Cited by 889
Perceived risk and perceptions of COVID-19 vaccine: A survey among general public in Pakistan
Beg, B. M., Hussain, T. A., Ahmad, M., Areej, S., Majeed, A., Rasheed, M. A., Ahmad, M. M., Shoaib, Q.-U.-A., & Aroosa, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266028 · Cited by 62
“Pfizer–BioNTech [9] and Moderna [10] developed by the mRNA technique exhibited good efficacy and safety profile.”
MethodModeling how antibody responses may determine the efficacy of COVID-19 vaccines
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00198-0 · Cited by 61
Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines
Fraser, R., Resendiz, A. O., Mazein, A., & Dockrell, D. H. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.01.003 · Cited by 65
“However, current licenced SARSCoV-2 vaccines induce predominantly systemic responses, rather than potent, durable responses in the URT mucosa [5-16].”
BackgroundLow, J. G., de Alwis, R., Chen, S., Kalimuddin, S., Leong, Y. S., Mah, T. K. L., Yuen, N., Tan, H. C., Zhang, S. L., Sim, J. X. Y., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00590-x · Cited by 61
An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
Chi, X., Zhang, X., Pan, S., Yu, Y., Shi, Y., Lin, T., Duan, H., Liu, X., Chen, W., Yang, X., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00912-4 · Cited by 69
“In this study, we obtain several SARS-CoV-2 RBD targeting Nbs with either high-affinity or broad neutralization spectrum using a previously developed synthetic nanobody discovery platform.(10) We identified a biparatopic Nb as the best in class broadly neutralizing antibody, which can potently neutralize more than 60…”
MethodImmunopeptidomics for next-generation bacterial vaccine development
Mayer, R. L., & Impens, F. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.04.010 · Cited by 65
“especially mRNA vaccines conferring over 90% protection against coronavirus disease 2019 (Covid-19) [22,23] This has”
BackgroundLodato, F., Larocca, A., D’Errico, A., & Cennamo, V. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.005 · Cited by 63
“[2] Rocco A, Sgamato C, Compare D, Nardone G.”
BackgroundMultiple COVID-19 Waves and Vaccination Effectiveness in the United States
Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042282 · Cited by 66
“To date, results from both clinical trials [50] and real-world data analysis [51] confirm the effectiveness of the vaccine (e.”
ResultSite-Specific Steric Control of SARS-CoV-2 Spike Glycosylation
Allen, J. D., Chawla, H., Samsudin, F., Zuzic, L., Shivgan, A. T., Watanabe, Y., He, W., Callaghan, S., Song, G., Yong, P., et al. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00279 · Cited by 65
Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T. (2021) · mBio · doi:10.1128/mbio.01386-21 · Cited by 68
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV
Matarazzo, L., & Bettencourt, P. J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172691 · Cited by 77
Martins‐Filho, P. R., Ferreira, L. C., Heimfarth, L., Araújo, A. A. D. S., & Quintans‐Júnior, L. J. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100062 · Cited by 68
Ongoing Clinical Trials of Nonviral siRNA Therapeutics
Narasipura, E. A., VanKeulen‐Miller, R., Ma, Y., & Fenton, O. S. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00205 · Cited by 69
Chow, K. W., Pham, N. V., Ibrahim, B. M., Hong, K. N., & Saab, S. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07504-w · Cited by 61
“During the initial phase III pre-approval clinical trials, several potential adverse effects were identified, such as Bell’s palsy [3] and lymphadenopathy [6].”
BackgroundSeroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
Hsu, C. M., Weiner, D. E., Manley, H. J., Aweh, G. N., Ladik, V., Frament, J., Miskulin, D., Agyropoulos, C., Abreo, K. D., Chin, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12250921 · Cited by 61
Ippolito, G., Vecchia, A. L., Umbrello, G., Pietro, G. M. D., Bono, P., Catenacci, S. S., Pinzani, R., Tagliabue, C., Bosis, S., Agostoni, C. V., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.721005 · Cited by 63
“Thirtyseven patients (20,8%) had a diagnosis of one or more concurring chronic diseases, cardiovascular diseases (14), gastrointestinal disease (9), neurologic disease (9), pulmonary disease (8), and hepatic disease (2), respectively; 16 had multi-organ disease.”
BackgroundAlhassan, R. K., Owusu‐Agyei, S., Ansah, E., & Gyapong, M. (2021) · Human Resources for Health · doi:10.1186/s12960-021-00657-1 · Cited by 61
Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study
Shasha, D., Bareket, R., Sikron, F. H., Gertel, O., Tsamir, J., Dvir, D., Mossinson, D., Heymann, A. D., & Zacay, G. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.018 · Cited by 60
“Reported safety data by Pfizer andModerna [2,5,6,14] showed seven cases of Bell's palsy compared with one case in the placebo arm, among nearly 40 000 vaccinees, raising safety concerns.”
BackgroundmRNA vaccines: A matter of delivery
Cao, Y., & Gao, G. F. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100746 · Cited by 61
Li, Z., Zhang, X., Ho, W., Bai, X., Jaijyan, D. K., Li, F., Kumar, R., Kolloli, A., Subbian, S., Zhu, H., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204462 · Cited by 67
Bonelli, M. M., Mrak, D., Tobudic, S., Sieghart, D., Koblischke, M., Mandl, P., Kornek, B., Simader, E., Radner, H., Perkmann, T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221558 · Cited by 64
“In our trial, typical general systemic reactions (like fever, myalgias, and similar) were observed, that were within the scope of the reports from the large . approval studies 22–24 , with some numerical differences seen between the two treatment groups.”
BackgroundCoagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
Kastenhuber, E. R., Mercadante, M., Nilsson-Payant, B. E., Johnson, J. L., Jaimes, J. A., Muecksch, F., Weisblum, Y., Bram, Y., Chandar, V., Whittaker, G. R., et al. (2022) · eLife · doi:10.7554/elife.77444 · Cited by 65
“Despite the recent success of vaccines (Baden et al., 2021; Polack et al., 2020), the limited world- wide vaccine distribution (Kwok et al.”
BackgroundSingle-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine
Kramer, K. J., Wilfong, E. M., Voss, K., Barone, S. M., Shiakolas, A. R., Raju, N., Roe, C. E., Suryadevara, N., Walker, L. M., Wall, S. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31142-5 · Cited by 61
Lim, C. T., Tan, K. W., Wu, M., Ulferts, R., Armstrong, L. A., Ozono, E., Drury, L. S., Milligan, J. C., Zeisner, T. U., Zeng, J., et al. (2021) · Biochemical Journal · doi:10.1042/bcj20210244 · Cited by 58
Brasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S. A., Intinis, C. D., Fesi, F., Gizzi, K., Macagno, M., Montone, M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01313-z · Cited by 62
Horne, E. M. F., Hulme, W. J., Keogh, R. H., Palmer, T. M., Williamson, E. J., Parker, E. P. K., Green, A., Walker, V., Walker, A. J., Curtis, H., et al. (2022) · BMJ · doi:10.1136/bmj-2022-071249 · Cited by 60
(2021) · doi:10.1101/2021.10.26.21265397 · Cited by 153
Li, X., Burn, E., Duarte‐Salles, T., Yin, C., Reich, C., Delmestri, A., Verhamme, K. M. C., Rijnbeek, P. R., Suchard, M. A., Li, K., et al. (2022) · BMJ · doi:10.1136/bmj-2022-071594 · Cited by 67
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 68
Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J. L., Edmond, M. B., Doll, M. E., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2021.12.035 · Cited by 65
“Clin Infect Dis 2005; 41 (1):77–82 an official publication of the Infectious Diseases Society of America .”
BackgroundMoore, J. P. (2021) · JAMA · doi:10.1001/jama.2021.3465 · Cited by 60
Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA
Miao, H., Huang, K., Li, Y., Li, R., Zhou, X., Shi, J., Tong, Z., Sun, Z., & Yu, A. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123050 · Cited by 70
Fraley, E., LeMaster, C., Geanes, E. S., Banerjee, D., Khanal, S., Grundberg, E., Selvarangan, R., & Bradley, T. (2021) · BMC Medicine · doi:10.1186/s12916-021-02055-9 · Cited by 65
Khairallah, P., Aggarwal, N., Awan, A. A., Vangala, C., Airy, M., Pan, J. S.-C., Murthy, B. V. R., Winkelmayer, W. C., & Ramanathan, V. (2021) · Transplant International · doi:10.1111/tri.13840 · Cited by 74
RNA modification in mRNA cancer vaccines
Mei, Y., & Wang, X. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01020-5 · Cited by 62
COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals
Chavda, V. P., Vora, L. K., & Vihol, D. R. (2021) · Clinical Complementary Medicine and Pharmacology · doi:10.1016/j.ccmp.2021.100004 · Cited by 65
SARS‐CoV‐2 and its variants of concern including Omicron: A never ending pandemic
Mohapatra, R. K., Kuppili, S., Suvvari, T. K., Kandi, V., Behera, A., Verma, S., Kudrat‐E‐Zahan, Biswal, S. K., AL-Noor, T. H., El‐ajaily, M. M., et al. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14035 · Cited by 64
SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention
Rubin, E. J., & Longo, D. L. (2020) · New England Journal of Medicine · doi:10.1056/nejme2034717 · Cited by 66
Dreyer-Alster, S., Menascu, S., Mandel, M., Shirbint, E., Magalashvili, D., Dolev, M., Flechter, S., Givon, U., Guber, D., Stern, Y., et al. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120155 · Cited by 60
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.